IGF-1 LR3
Also known as: Long R3 IGF-1, LR3-IGF-1
A modified IGF-1 with extended half-life and enhanced potency.
Overview
IGF-1 LR3 is a modified form of insulin-like growth factor-1 with an arginine substitution at position 3 and a 13 amino acid extension. These modifications reduce IGF binding protein affinity, increasing bioactivity.
Mechanism of Action
Activates IGF-1 receptors with higher potency than native IGF-1 due to reduced IGFBP sequestration. Promotes protein synthesis, cellular proliferation, and inhibits apoptosis.
Pharmacokinetics
Extended half-life (~20-30 hours) compared to native IGF-1 (~15 minutes). Greater tissue exposure and bioactivity.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Research
20-50 mcg
Once daily
4-6 weeks
Post-workout or morning; monitor glucose
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 12-3x more potent than native IGF-1 in cell proliferation
- 2Significantly longer half-life than native IGF-1
- 3Widely used in cell culture and research
- 4Anabolic effects on skeletal muscle
Side Effects & Contraindications
Reported Side Effects
- Hypoglycemia
- Joint pain
- Water retention
Contraindications
- Active malignancy
- Diabetes
- Pregnancy
Safety Considerations
Hypoglycemia risk. Theoretical cancer concerns due to mitogenic effects. Requires careful dosing.
Storage Requirements
Store lyophilized at -20C. Very temperature sensitive.
Scientific References
- 1